Navigation Links
Global Immune Check Point Inhibitors Market & Clinical Pipeline Insight 2022 - Immunotherapy Represents a Paradigm Shift in Cancer Therapy Along Multiple Fronts - Research and Markets
Date:3/22/2017

DUBLIN, Mar 22, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Immune Check Point Inhibitors Market & Clinical Pipeline Insight 2022" drug pipelines to their offering.

Global Immune Check Point Inhibitors Market & Clinical Pipeline Insight 2022 report gives comprehensive insight on clinical and non-clinical aspects involved in the development and integration of immune check point inhibitors as main streamline drugs in the immunotherapy treatment. Report helps to identify the basic classification and molecular mechanism of action of immune check point inhibitors drugs available in the market and in the clinical pipeline.  Currently there are 4 Immune Check Point Inhibitors drugs commercially available in the market and more than 70 drugs in clinical pipeline.

Immunotherapy represents a paradigm shift in cancer therapy along the multiple fronts. Although, targeted therapy upgrades the underlying signaling defect which results in oncogenesis within the tumor. The immune checkpoint blockade is fundamentally a therapy which directed at the patient's native immune system to tilt the immune homeostasis away from self-tolerance towards cytotoxicity, with the goal of inducing anti-tumor immunity.

The immune checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab were approved by FDA and are indicated for the treatment of squamous non-small cell lung cancer and metastatic melanoma, respectively. Several other anti PD-1 drugs are in late stage clinical trials and are expected to achieve the regulatory approval in the near future. Moreover, the anti PD-L1, antibody which targets the tumor cells rather than the T cells is also being studied and tested.

Immune checkpoint inhibitors appears to offer an advantage compared with standard cytotoxic chemotherapy and produces high response rates, durable response and the survival curves which indicate the sustained remission of long therapy which has been completed. Safety with the new therapies is of concern since the immune system is being suppressed by the cancer and the immune checkpoint inhibitors are turning the suppressed immune system.

Companies Mentioned

  • Advaxis
  • Agenus
  • Amgen
  • Bristol Myers Squibb
  • Faron Pharmaceuticals
  • Genentech
  • Genocea
  • Incyte Corporation
  • Innate Pharma
  • Kite Pharma
  • MacroGenics
  • Merck
  • NewLink Genetics Corp
  • Sorrento Therapeutics
  • TG Therapeutics

Key Topics Covered:

1. Immune Checkpoint Inhibitors- Introduction to Next Generation Cancer Immunotherapy

2. Major Immune Checkpoints Proteins

3. Mechanism of Action of Immune Checkpoint Inhibitors

4. CTLA 4 Inhibition Approved Drugs to Target Immune Checkpoints

5. PD-1 & PD-L1 Inhibition Approved Drugs to Target Immune Checkpoints

6. Biomarkers Associated with Immune Checkpoint Inhibitors

7. Combination Approaches with Immune Checkpoint Inhibitors

8. Global Immune Checkpoint Inhibitors Market

9. Global Immune Checkpoint Inhibitors Clinical Pipeline

10. Global Immune Checkpoint Inhibitors Market Dynamics

11. Future Potential of Immune Checkpoint Inhibitors

12. PDL1-Protein-Inhibitors Clinical Pipeline by Company, Indication  & Phase

13. Marketed PDL1-Protein-Inhibitors Clinical Insight by Company & Phase

14. CTLA-4-Inhibitors Clinical Pipeline by Company, Indication & Phase

15. Marketed CTLA-4-Inhibitors Clinical Insight by Company, Phase & Indication

16. PD-1-Protein-Inhibitors Clinical Pipeline by Company, Phase & Indication

17. Marketed PD-1-Protein-Inhibitors Clinical Insight by Company & Phase

18. Competitive Landscape

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/jkc62j/global_immune

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-immune-check-point-inhibitors-market--clinical-pipeline-insight-2022---immunotherapy-represents-a-paradigm-shift-in-cancer-therapy-along-multiple-fronts---research-and-markets-300427893.html


'/>"/>
SOURCE Research and Markets
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Information Online Market Research Portal Provides Complimentary Sample Service for Customers to Preview Reports by Global Industry Analysts
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. The Rockley Group and Content Rules Ink Deal to Extend Global Reach
4. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
5. Amgen To Present At The UBS Global Life Sciences Conference
6. HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
8. PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems
9. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
10. TRACE Releases 2012 Global Enforcement Report
11. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... , May 4, 2017  A new tight-tolerance ... and other highly-engineered materials, is being launched by ... has been developed in recent years to service ... and surgical applications. More expensive materials such as ... microextrusion tubing due to their ability to consistently ...
(Date:5/3/2017)...  Getinge, a leading global provider of products ... cost efficiency within healthcare and life sciences, today ... demonstrating that intra-aortic balloon counterpulsation (IABC) appears effective ... The single-center, retrospective, observational study showed that use ... 50cc intra-aortic balloon (IAB) in contemporary practice ...
(Date:5/2/2017)... Iowa , May 2, 2017  CIVCO ... patient-centric radiotherapy solutions, announced today that Nat ... been with CIVCO since 2012 and has served ... management, senior vice president and general manager, and ... "I am extremely proud of what ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... , ... Orbita’s Nathan Treloar will discuss the role of voice-powered healthcare applications ... Connected Health and IoT: Technology Innovators and Disruption , the workshop is part of ... research and consulting firm specializing in emerging consumer technology products and services. , ...
(Date:5/23/2017)... ... , ... Patients in need of a pulpotomy in Mt. Horeb, ... with or without a referral. Dr. Cotey is a respected dental provider of general ... healthy alternative to a tooth extraction. , When a child has a severely infected ...
(Date:5/22/2017)... (PRWEB) , ... May 22, 2017 , ... Today, Our ... Washington, MO with a public ribbon cutting ceremony. Since opening over a ... an alternative to the emergency room. The new Our Urgent Care walk-in clinic ...
(Date:5/22/2017)... ... ... Faithfully following pop culture, people today are forever in pursuit of physical ... programs. It carries on to skin nourished, pampered and nurtured to be soft and ... CDA has found that just like a perfectly cut and polished diamond, that ...
(Date:5/21/2017)... (PRWEB) , ... May 19, 2017 , ... ... pleased to announce the appointment of James (Jim) Vertino as Chief Information Officer ... a proven, transformational leader who drives innovation and business performance. He defines strategic ...
Breaking Medicine News(10 mins):